2006
DOI: 10.1007/s00213-006-0567-0
|View full text |Cite
|
Sign up to set email alerts
|

Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors

Abstract: The antiparkinson agent, S32504, displays DS properties principally mediated by high-efficacy activation of D(2) receptors Antipsychotics known to act as partial agonists at D(2)/D(3) receptors attenuate DS properties of S32504, actions reflecting their low efficacy at these sites.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
12
0

Year Published

2008
2008
2017
2017

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(15 citation statements)
references
References 78 publications
(156 reference statements)
3
12
0
Order By: Relevance
“…Consistent with our findings, PG01037 has been found to localize primarily in D3-rich brain regions as determined by pharmacological magnetic resonance imaging (Grundt et al, 2007b) and selectively attenuate the D3-mediated component of quinpirole-induced yawning in rats (Baladi et al, 2010). Unlike PG01037, L-741626 attenuated the cocaine-like DS effects of both sumanirole and PD128907, suggesting less selective effects consistent with previous studies in which L-741626 attenuated the DS effects of another D3 agonist, S32504 [(ϩ)-trans-3,4,4a,5,6, 10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] (Millan et al, 2007). Given the modest in vitro receptor subtype selectivity of both L-741626 (ϳ15-fold D2/D3; Grundt et al, 2007a) and PD128907 (ϳ13-fold D3/D2; Pugsley et al, 1995), it is possible that L-741626 and/or PD128907 were active at both re- ceptor subtypes at the doses tested.…”
Section: Discussionsupporting
confidence: 85%
“…Consistent with our findings, PG01037 has been found to localize primarily in D3-rich brain regions as determined by pharmacological magnetic resonance imaging (Grundt et al, 2007b) and selectively attenuate the D3-mediated component of quinpirole-induced yawning in rats (Baladi et al, 2010). Unlike PG01037, L-741626 attenuated the cocaine-like DS effects of both sumanirole and PD128907, suggesting less selective effects consistent with previous studies in which L-741626 attenuated the DS effects of another D3 agonist, S32504 [(ϩ)-trans-3,4,4a,5,6, 10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] (Millan et al, 2007). Given the modest in vitro receptor subtype selectivity of both L-741626 (ϳ15-fold D2/D3; Grundt et al, 2007a) and PD128907 (ϳ13-fold D3/D2; Pugsley et al, 1995), it is possible that L-741626 and/or PD128907 were active at both re- ceptor subtypes at the doses tested.…”
Section: Discussionsupporting
confidence: 85%
“…Consistent with studies that examined the discriminative stimulus effects of direct-acting dopamine receptor agonists across different feeding conditions (Appel et al 1988; Baker et al 1999; Baladi et al 2010; Bristow et al 1998; Christian et al 2001; Katz and Alling 2000; Kleven and Koek 1997; Koffarnus et al 2009; Millan et al 2000, 2007), it appears as though D3 receptors have a predominant role in mediating the discriminative stimulus effects of the indirect-acting dopamine receptor agonist cocaine in free-feeding rats whereas both D2 and D3 (and perhaps other) receptors mediate the discriminative stimulus effects of cocaine in food-restricted rats (also see Achat-Mendes et al 2010). …”
Section: Discussionsupporting
confidence: 70%
“…potency) to drugs acting at dopamine receptors (Baladi et al 2011; Collins et al 2008; Sevak et al 2008), with one study demonstrating that different dopamine receptors mediate the discriminative stimulus effects of quinpirole depending on feeding condition (Baladi et al 2010). Specifically, a number of studies have reported that the discriminative stimulus effects of nonselective D2/D3 dopamine receptor agonists, like quinpirole, are mediated by dopamine D2 receptors (Appel et al 1988; Baker et al 1999; Bristow et al 1998; Christian et al 2001; Katz and Alling 2000; Kleven and Koek 1997; Koffarnus et al 2009; Millan et al 2000, 2007). Those studies used food to maintain responding, thereby necessitating food restriction throughout the experiment.…”
Section: Introductionmentioning
confidence: 99%
“…The discriminative stimulus effects of a variety of DA receptor agonists that bind to both D3 and D2 receptors are thought to be mediated by D2 receptors (Kleven and Koek, 1997;Bristow et al, 1998;Baker et al, 1999;Katz and Alling, 2000;Millan et al, 2000Millan et al, , 2007Christian et al, 2001;Koffarnus et al, 2009) based on results of studies that used DA receptor antagonists to attenuate the effects of DA receptor agonists; however, most studies used food-restricted rats. In the current study, quinpirole dose-response curves were determined in the presence of different doses of antagonists that vary in their selectivity for D3 and D2 receptors.…”
Section: Discussionmentioning
confidence: 99%
“…Collectively, studies conducted with rats suggest that the discriminative stimulus effects of a number of DA receptor agonists that bind to both D3 and D2 receptors are mediated through D2 receptors (Appel et al, 1988;Kleven and Koek, 1997;Bristow et al, 1998;Baker et al, 1999;Katz and Alling, 2000;Millan et al, 2000Millan et al, , 2007Christian et al, 2001;Koffarnus et al, 2009). For example, the discriminative stimulus effects of the D3/D2 receptor agonist S32504 are antagonized by the D2 receptorselective antagonist L-741,626 but not by the D3 receptor-selective antagonist S33084 (Millan et al, 2007), suggesting that the selective binding of S32504 to D3 receptors does not correlate with receptors mediating its discriminative stimulus effects. Moreover, the discriminative stimulus effects of the D3/D2 receptor agonist (ϩ)-PD 128,907 are antagonized by the D2 receptor-selective antagonist L-741,626 and not by the D3 receptor-selective antagonist GR 103,691 (Bristow et al, 1998).…”
mentioning
confidence: 99%